Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

4.17

Mkt cap

14M

Volume

77K

High

4.41

P/E Ratio

-0.10

52-wk high

20.83

Low

4.17

Div yield

N/A

52-wk low

1.80

Cingulate Inc. has completed a financing transaction, securing $5 million in net proceeds from an accredited investor. This funding will support the company's development of pharmaceutical products using its Precision Timed Release™ technology.

Portfolio Pulse from

December 23, 2024 | 12:45 pm

Cingulate has reported its third quarter 2024 financial results, highlighting a $19.5 million increase in working capital. This financial boost is aimed at advancing their lead ADHD drug, CTx-1301, with a New Drug Application (NDA) submission expected by mid-2025.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Cingulate's CEO and Chairman, Shane Schaffer, has been charged with aggravated domestic battery as per an SEC filing. This legal issue could impact the company's leadership and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 8:37 pm

Cingulate has filed for the resale of up to 1.5 million shares by a selling stockholder, as per the SEC filing. This move could impact the stock's supply and demand dynamics.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 10:27 am

Cingulate shares are trading lower following the announcement of the commencement of a final FDA-required food effect study for CTx-1301, a treatment for ADHD.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:20 pm

Cingulate has initiated the final study for its lead ADHD treatment, CTx-1301, and has raised over $10 million in additional capital since mid-August.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:33 pm

In August 2024, Nvidia was the most-searched stock on Benzinga Pro, driven by strong earnings and guidance. Tesla, SPY, and QQQ were also among the top-searched tickers. Lumen Technologies and GeoVax Labs entered the top 10 due to financial results and health-related interest, respectively.

Portfolio Pulse from Chris Katje

September 03, 2024 | 4:12 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Notable gainers included Theriva Biologics, WORK Medical Technology, and Cingulate, while Catheter Precision and NuCana were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 02, 2024 | 4:30 pm

Cingulate Inc. (NASDAQ:CING) shares are experiencing a significant rise, driven by the announcement of their Precision Timed Release (PTR) technology for ADHD treatment and a positive valuation note from Zacks Small-Cap Research. The stock has seen a 15% increase, with a notable decrease in short interest.

Portfolio Pulse from Vaishali Prayag

August 30, 2024 | 7:23 pm

Cingulate's short interest has decreased by 75.73%, with 51,000 shares sold short, representing 3.18% of its float. This is higher than its peers' average of 2.77%. A decrease in short interest can indicate a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

August 27, 2024 | 2:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.